The state of Florida currently has 200 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
NCT06238921
Recruiting
This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
NCT06100874
Recruiting
This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: * Sacituzumab govitecan (a type of antibody-drug conjugate) * Trastuzumab (Herceptin) (a type of monoclonal antibody) * Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) (a type of recombinant monoclonal antibody) * Trast... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Miami Cancer Institute at Baptist Health, Miami, Florida
Conditions: Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
Register for Updates
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
NCT06691035
Recruiting
This is a pilot study to determine feasibility and safety of the combination of Dendritic Cell (DC1) vaccines and elacestrant in patients with hormone positive HER2 negative metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer Metastatic Breast Cancer, HER2-negative Breast Cancer
Register for Updates
A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer
NCT06327490
Recruiting
Breast cancer is estimated to affect approximately 300,000 women in the US in 2023. Studies demonstrate that 1 in 5 will develop breast cancer related lymphedema secondary to the treatments that they receive. BCRL at this time has no cure, however early detection can prevent the progression to late stage BCRL. At this time a technique of arm massage, manual lymphatic drainage (MLD), is used for treatment. This study investigates a new method of MLD, which is guided by the individual patients' ly... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/05/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Breast Cancer
Register for Updates
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
NCT06409390
Recruiting
The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers hope could be more effective in treating metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Metastatic Breast Cancer
Register for Updates
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NCT05896189
Recruiting
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/01/2025
Locations: John Fitzgerald Kennedy Medical Center, Atlantis, Florida +13 locations
Conditions: Breast Cancer, Cognitive Impairments
Register for Updates
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT05563220
Recruiting
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Advent Health (Florida Hospital) - Altamonte Springs, Altamonte Springs, Florida +2 locations
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942
Recruiting
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Investigative Site #104, Lake Mary, Florida
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
Register for Updates
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864
Recruiting
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Research Site, Jacksonville, Florida +3 locations
Conditions: Breast Cancer
Register for Updates
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
NCT05900986
Recruiting
The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) injection in female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary objective of this study, followed by efficacy that will be assessed fr... Read More
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
04/23/2025
Locations: Integro Theranostics Research Site #9, Weston, Florida
Conditions: Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
Register for Updates
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT03606967
Recruiting
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida +9 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Invasive Breast Carcinoma
Register for Updates
Robotic vs. Open NSM for Early Stage Breast Cancer
NCT05720039
Recruiting
This study evaluates the safety and effectiveness of the da Vinci SP Surgical System compared to Open NSM in Nipple Sparing Mastectomy procedures.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/22/2025
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Breast Cancer Female, Breast Cancer, Breast Cancer, Early-Onset, Breast Disease, Breast
Register for Updates